Published in Breast Cancer Res on August 23, 1999
Testing an Intelligent Tutoring System to Enhance Genetic Risk Assessment | NCT03511690
Genome-wide association study identifies novel breast cancer susceptibility loci. Nature (2007) 29.23
A comprehensive model for familial breast cancer incorporating BRCA1, BRCA2 and other genes. Br J Cancer (2002) 4.18
The BOADICEA model of genetic susceptibility to breast and ovarian cancer. Br J Cancer (2004) 4.06
The BOADICEA model of genetic susceptibility to breast and ovarian cancers: updates and extensions. Br J Cancer (2008) 3.87
A genome wide linkage search for breast cancer susceptibility genes. Genes Chromosomes Cancer (2006) 2.35
Association between common variation in 120 candidate genes and breast cancer risk. PLoS Genet (2007) 2.27
Pregnancies, breast-feeding, and breast cancer risk in the International BRCA1/2 Carrier Cohort Study (IBCCS). J Natl Cancer Inst (2006) 2.25
Genetic susceptibility loci for breast cancer by estrogen receptor status. Clin Cancer Res (2008) 1.72
U-statistics-based tests for multiple genes in genetic association studies. Ann Hum Genet (2008) 1.53
The BARD1 Cys557Ser variant and breast cancer risk in Iceland. PLoS Med (2006) 1.53
Genome-wide association studies of cancer. J Clin Oncol (2010) 1.45
Mutation analysis of the CHK2 gene in families with hereditary breast cancer. Br J Cancer (2001) 1.39
Kin-cohort estimates for familial breast cancer risk in relation to variants in DNA base excision repair, BRCA1 interacting and growth factor genes. BMC Cancer (2004) 1.36
Racial differences in the incidence of BRCA1 and BRCA2 mutations in a cohort of early onset breast cancer patients: African American compared to white women. J Med Genet (2005) 1.24
Role of WISP-2/CCN5 in the maintenance of a differentiated and noninvasive phenotype in human breast cancer cells. Mol Cell Biol (2007) 1.18
Screening for BRCA1, BRCA2, CHEK2, PALB2, BRIP1, RAD50, and CDH1 mutations in high-risk Finnish BRCA1/2-founder mutation-negative breast and/or ovarian cancer individuals. Breast Cancer Res (2011) 1.17
Common genetic variation in candidate genes and susceptibility to subtypes of breast cancer. Cancer Epidemiol Biomarkers Prev (2009) 1.15
Association of single-nucleotide polymorphisms in the cell cycle genes with breast cancer in the British population. Carcinogenesis (2008) 1.11
Tagging single nucleotide polymorphisms in the BRIP1 gene and susceptibility to breast and ovarian cancer. PLoS One (2007) 1.08
Familial risks of breast cancer. Breast Cancer Res (2002) 1.07
A comprehensive focus on global spectrum of BRCA1 and BRCA2 mutations in breast cancer. Biomed Res Int (2013) 1.02
Identification of common variants in the SHBG gene affecting sex hormone-binding globulin levels and breast cancer risk in postmenopausal women. Cancer Epidemiol Biomarkers Prev (2008) 1.01
Polygenic susceptibility to breast cancer: current state-of-the-art. Future Oncol (2009) 0.98
CHEK2 variants in susceptibility to breast cancer and evidence of retention of the wild type allele in tumours. Br J Cancer (2002) 0.97
Autophagy in cancer. F1000Prime Rep (2015) 0.96
Genome-wide association study of circulating estradiol, testosterone, and sex hormone-binding globulin in postmenopausal women. PLoS One (2012) 0.95
BAP1 and breast cancer risk. Fam Cancer (2005) 0.94
Effects of age on the detection and management of breast cancer. Cancers (Basel) (2015) 0.94
Genetic variants associated with breast cancer risk for Ashkenazi Jewish women with strong family histories but no identifiable BRCA1/2 mutation. Hum Genet (2013) 0.90
Mutation analysis and characterization of ATR sequence variants in breast cancer cases from high-risk French Canadian breast/ovarian cancer families. BMC Cancer (2006) 0.90
Genetic variants underlying risk of endometriosis: insights from meta-analysis of eight genome-wide association and replication datasets. Hum Reprod Update (2014) 0.90
PIK3CA and TP53 gene mutations in human breast cancer tumors frequently detected by ion torrent DNA sequencing. PLoS One (2014) 0.89
Expression of TopBP1 in hereditary breast cancer. Mol Biol Rep (2012) 0.89
Interactions between genes involved in the antioxidant defence system and breast cancer risk. Br J Cancer (2006) 0.86
A two-stage association study identifies methyl-CpG-binding domain protein 2 gene polymorphisms as candidates for breast cancer susceptibility. Eur J Hum Genet (2012) 0.84
Breast cancer risk assessment using genetic variants and risk factors in a Singapore Chinese population. Breast Cancer Res (2014) 0.84
Common genetic variants in pre-microRNAs and risk of breast cancer in the North Indian population. Ecancermedicalscience (2014) 0.83
Integrative analyses of conserved WNT clusters and their co-operative behaviour in human breast cancer. Bioinformation (2011) 0.83
Contribution of the Defective BRCA1, BRCA2 and CHEK2 Genes to the Familial Aggregation of Breast Cancer: a Simulation Study Based on the Swedish Family-Cancer Database. Hered Cancer Clin Pract (2004) 0.82
Can a phenotype for recessive inheritance in breast cancer be defined? Fam Cancer (2010) 0.82
Lack of association between BARD1 Cys557Ser variant and breast cancer risk: a meta-analysis of 11,870 cases and 7,687 controls. J Cancer Res Clin Oncol (2011) 0.82
A common polymorphism near the ESR1 gene is associated with risk of breast cancer: evidence from a case-control study and a meta-analysis. PLoS One (2012) 0.82
Li-Fraumeni-like syndrome associated with a large BRCA1 intragenic deletion. BMC Cancer (2012) 0.81
A Common SNP of IL-10 (-1082A/G) is Associated With Increased Risk of Premenopausal Breast Cancer in South Indian Women. Iran J Cancer Prev (2015) 0.81
Common variation in EMSY and risk of breast and ovarian cancer: a case-control study using HapMap tagging SNPs. BMC Cancer (2005) 0.81
Influence of germline polymorphisms of GSTT1, GSTM1, and GSTP1 in familial versus sporadic breast cancer susceptibility and survival. Fam Cancer (2007) 0.81
Inferring synthetic lethal interactions from mutual exclusivity of genetic events in cancer. Biol Direct (2015) 0.81
The DNA2 nuclease/helicase is an estrogen-dependent gene mutated in breast and ovarian cancers. Oncotarget (2014) 0.80
Mcs5c: a mammary carcinoma susceptibility locus located in a gene desert that associates with tenascin C expression. Cancer Prev Res (Phila) (2011) 0.80
CHEK2 1100delC is prevalent in Swedish early onset familial breast cancer. BMC Cancer (2007) 0.80
A model of gene-gene and gene-environment interactions and its implications for targeting environmental interventions by genotype. Theor Biol Med Model (2006) 0.79
Thrombin-activatable fibrinolysis inhibitor Thr325Ile polymorphism and plasma level in breast cancer: A pilot study. Meta Gene (2015) 0.79
The application of nonsense-mediated mRNA decay inhibition to the identification of breast cancer susceptibility genes. BMC Cancer (2012) 0.76
Prospective study of high-risk, BRCA1/2-mutation negative women: the 'negative study'. BMC Cancer (2014) 0.76
Loss of the BRCA1-interacting helicase BRIP1 results in abnormal mammary acinar morphogenesis. PLoS One (2013) 0.76
Interaction between APC and Fen1 during breast carcinogenesis. DNA Repair (Amst) (2016) 0.76
Dissecting genetic risk factors in breast cancer. Oncotarget (2017) 0.75
Intronic TP53 Germline Sequence Variants Modify the Risk in German Breast/Ovarian Cancer Families. Hered Cancer Clin Pract (2004) 0.75
The Role of Knowledge on Genetic Counseling and Testing in Black Cancer Survivors at Increased Risk of Carrying a BRCA1/2 Mutation. J Genet Couns (2016) 0.75
BRCA1 and BRCA1 Genes and Inherited Breast and/or Ovarian Cancer: Benefits of Genetic Testing. Indian J Surg Oncol (2011) 0.75
Performance Characterization and Validation of Saliva as an Alternative Specimen Source for Detecting Hereditary Breast Cancer Mutations by Next Generation Sequencing. Int J Genomics (2016) 0.75
In search of breast cancer culprits: suspecting the suspected and the unsuspected. Breast Cancer (Auckl) (2008) 0.75
Genetic variants in the acylphosphatase 2 gene and the risk of breast cancer in a Han Chinese population. Oncotarget (2016) 0.75
Time-Delayed Models of Gene Regulatory Networks. Comput Math Methods Med (2015) 0.75
Multiple susceptibility loci for radiation-induced mammary tumorigenesis in F2[Dahl S x R]-intercross rats. PLoS One (2013) 0.75
Assessing the Racial and Ethnic Disparities in Breast Cancer Mortality in the United States. Int J Environ Res Public Health (2017) 0.75
Breast Cancer Risk Estimation and Personal Insurance: A Qualitative Study Presenting Perspectives from Canadian Patients and Decision Makers. Front Genet (2017) 0.75
A route to new cancer therapies: the FA pathway is essential in BRCA1- or BRCA2-deficient cells. Nat Struct Mol Biol (2016) 0.75
Detection of false positive mutations in BRCA gene by next generation sequencing. Fam Cancer (2016) 0.75
Characterization of single-nucleotide polymorphisms in coding regions of human genes. Nat Genet (1999) 24.24
Pathology of familial breast cancer: differences between breast cancers in carriers of BRCA1 or BRCA2 mutations and sporadic cases. Breast Cancer Linkage Consortium. Lancet (1997) 18.24
Patterns of single-nucleotide polymorphisms in candidate genes for blood-pressure homeostasis. Nat Genet (1999) 17.09
Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science (1990) 16.68
Linkage of early-onset familial breast cancer to chromosome 17q21. Science (1990) 16.21
Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium. Am J Hum Genet (1998) 15.09
Localization of a breast cancer susceptibility gene, BRCA2, to chromosome 13q12-13. Science (1994) 8.73
Incidence of cancer in 161 families affected by ataxia-telangiectasia. N Engl J Med (1991) 8.19
Genetic analysis of breast cancer in the cancer and steroid hormone study. Am J Hum Genet (1991) 7.87
Prevalence of BRCA1 and BRCA2 gene mutations in patients with early-onset breast cancer. J Natl Cancer Inst (1999) 6.48
Systematic population-based assessment of cancer risk in first-degree relatives of cancer probands. J Natl Cancer Inst (1994) 6.27
Assessing the role of HLA-linked and unlinked determinants of disease. Am J Hum Genet (1987) 5.47
Age at onset as an indicator of familial risk of breast cancer. Am J Epidemiol (1990) 4.60
Family history and the risk of breast cancer: a systematic review and meta-analysis. Int J Cancer (1997) 4.47
Estimates of the gene frequency of BRCA1 and its contribution to breast and ovarian cancer incidence. Am J Hum Genet (1995) 3.71
Heterozygous ATM mutations do not contribute to early onset of breast cancer. Nat Genet (1997) 3.66
Localization of the gene for Cowden disease to chromosome 10q22-23. Nat Genet (1996) 3.53
An association between the risk of cancer and mutations in the HRAS1 minisatellite locus. N Engl J Med (1993) 2.62
Molecular genotyping shows that ataxia-telangiectasia heterozygotes are predisposed to breast cancer. Cancer Genet Cytogenet (1996) 2.59
Cancer in twins: genetic and nongenetic familial risk factors. J Natl Cancer Inst (1997) 2.57
A systematic review of genetic polymorphisms and breast cancer risk. Cancer Epidemiol Biomarkers Prev (1999) 2.39
Cancer risks in A-T heterozygotes. Int J Radiat Biol (1994) 2.04
Familiality of cancer in Utah. Cancer Res (1994) 1.80
Strong indication for a breast cancer susceptibility gene on chromosome 8p12-p22: linkage analysis in German breast cancer families. Oncogene (1997) 1.61
Loss of heterozygosity and linkage analysis in breast carcinoma: indication for a putative third susceptibility gene on the short arm of chromosome 8. Oncogene (1995) 1.58
Possible linkage of the estrogen receptor gene to breast cancer in a family with late-onset disease. Am J Hum Genet (1991) 1.57
Cancer mortality in relatives of women with breast cancer: the OPCS Study. Office of Population Censuses and Surveys. Int J Cancer (1996) 1.40
Relationship between breast histopathology and family history of breast cancer. Cancer (1993) 1.38
A germline mutation in the androgen receptor gene in two brothers with breast cancer and Reifenstein syndrome. Nat Genet (1992) 1.34
Age-specific familial risks in common cancers of the offspring. Int J Cancer (1998) 1.25
Using age of onset to distinguish between subforms of breast cancer. Ann Hum Genet (1990) 0.93
Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet (2003) 18.67
Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium. Am J Hum Genet (1998) 15.09
Risks of cancer in BRCA1-mutation carriers. Breast Cancer Linkage Consortium. Lancet (1994) 9.60
Survival of patients with breast cancer attending Bristol Cancer Help Centre. Lancet (1990) 7.04
Prevalence of BRCA1 and BRCA2 gene mutations in patients with early-onset breast cancer. J Natl Cancer Inst (1999) 6.48
Systematic population-based assessment of cancer risk in first-degree relatives of cancer probands. J Natl Cancer Inst (1994) 6.27
Screening with magnetic resonance imaging and mammography of a UK population at high familial risk of breast cancer: a prospective multicentre cohort study (MARIBS). Lancet (2005) 6.18
Multifactorial analysis of differences between sporadic breast cancers and cancers involving BRCA1 and BRCA2 mutations. J Natl Cancer Inst (1998) 6.06
Family history and the risk of breast cancer: a systematic review and meta-analysis. Int J Cancer (1997) 4.47
A comprehensive model for familial breast cancer incorporating BRCA1, BRCA2 and other genes. Br J Cancer (2002) 4.18
The BOADICEA model of genetic susceptibility to breast and ovarian cancer. Br J Cancer (2004) 4.06
The BOADICEA model of genetic susceptibility to breast and ovarian cancers: updates and extensions. Br J Cancer (2008) 3.87
Estimates of the gene frequency of BRCA1 and its contribution to breast and ovarian cancer incidence. Am J Hum Genet (1995) 3.71
Localization of the gene for Cowden disease to chromosome 10q22-23. Nat Genet (1996) 3.53
Population-based estimate of the average age-specific cumulative risk of breast cancer for a defined set of protein-truncating mutations in BRCA1 and BRCA2. Australian Breast Cancer Family Study. Cancer Epidemiol Biomarkers Prev (1999) 3.29
Allele losses in the region 17q12-21 in familial breast and ovarian cancer involve the wild-type chromosome. Nat Genet (1992) 3.13
Consistent loss of the wild type allele in breast cancers from a family linked to the BRCA2 gene on chromosome 13q12-13. Oncogene (1995) 2.91
Predicting the likelihood of carrying a BRCA1 or BRCA2 mutation: validation of BOADICEA, BRCAPRO, IBIS, Myriad and the Manchester scoring system using data from UK genetics clinics. J Med Genet (2008) 2.81
Risk models for familial ovarian and breast cancer. Genet Epidemiol (2000) 2.75
Models of genetic susceptibility to breast cancer. Oncogene (2006) 2.69
High prevalence of the 999del5 mutation in icelandic breast and ovarian cancer patients. Cancer Res (1996) 2.43
A systematic review of genetic polymorphisms and breast cancer risk. Cancer Epidemiol Biomarkers Prev (1999) 2.39
Polygenic susceptibility to prostate and breast cancer: implications for personalised screening. Br J Cancer (2011) 2.28
Localization to Xq27 of a susceptibility gene for testicular germ-cell tumours. Nat Genet (2000) 2.26
A linked genetic marker for multiple endocrine neoplasia type 2A on chromosome 10. Nature (1987) 2.15
ATM mutations and phenotypes in ataxia-telangiectasia families in the British Isles: expression of mutant ATM and the risk of leukemia, lymphoma, and breast cancer. Am J Hum Genet (1998) 2.06
Specific morphological features predictive for the basal phenotype in grade 3 invasive ductal carcinoma of breast. Histopathology (2006) 1.98
Breast and ovarian cancer risks to carriers of the BRCA1 5382insC and 185delAG and BRCA2 6174delT mutations: a combined analysis of 22 population based studies. J Med Genet (2005) 1.91
A common variant in BRCA2 is associated with both breast cancer risk and prenatal viability. Nat Genet (2000) 1.80
Ovarian cancer risk in BRCA1 carriers is modified by the HRAS1 variable number of tandem repeat (VNTR) locus. Nat Genet (1996) 1.79
The genetics of breast and ovarian cancer. Br J Cancer (1995) 1.78
Apolipoprotein E genetic variation and Alzheimer's disease. a meta-analysis. Dement Geriatr Cogn Disord (1999) 1.73
Familial site-specific ovarian cancer is linked to BRCA1 on 17q12-21. Am J Hum Genet (1994) 1.71
CYP17 promoter polymorphism and breast cancer in Australian women under age forty years. J Natl Cancer Inst (2000) 1.69
Presymptomatic screening for multiple endocrine neoplasia type 2A with linked DNA markers. The MEN 2A International Collaborative Group. Lancet (1991) 1.68
Targeted prostate cancer screening in men with mutations in BRCA1 and BRCA2 detects aggressive prostate cancer: preliminary analysis of the results of the IMPACT study. BJU Int (2010) 1.60
Survival in familial, BRCA1-associated, and BRCA2-associated epithelial ovarian cancer. United Kingdom Coordinating Committee for Cancer Research (UKCCCR) Familial Ovarian Cancer Study Group. Cancer Res (1999) 1.51
Magnetic resonance imaging screening in women at genetic risk of breast cancer: imaging and analysis protocol for the UK multicentre study. UK MRI Breast Screening Study Advisory Group. Magn Reson Imaging (2000) 1.47
The contribution of germline BRCA1 and BRCA2 mutations to familial ovarian cancer: no evidence for other ovarian cancer-susceptibility genes. Am J Hum Genet (1999) 1.45
Cancer mortality in relatives of women with breast cancer: the OPCS Study. Office of Population Censuses and Surveys. Int J Cancer (1996) 1.40
HLA and inflammatory bowel disease. Lancet (1996) 1.39
Sampling distribution of summary linkage disequilibrium measures. Ann Hum Genet (2002) 1.36
After BRCA1 and BRCA2-what next? Multifactorial segregation analyses of three-generation, population-based Australian families affected by female breast cancer. Am J Hum Genet (2000) 1.34
A germline mutation in the androgen receptor gene in two brothers with breast cancer and Reifenstein syndrome. Nat Genet (1992) 1.34
Identification of a novel prostate cancer susceptibility variant in the KLK3 gene transcript. Hum Genet (2011) 1.32
Genetic heterogeneity and localization of a familial breast-ovarian cancer gene on chromosome 17q12-q21. Am J Hum Genet (1993) 1.29
CAG and GGC repeat polymorphisms in the androgen receptor gene and breast cancer susceptibility in BRCA1/2 carriers and non-carriers. Br J Cancer (2001) 1.27
Risk estimation and screening in families of patients with medullary thyroid carcinoma. Lancet (1988) 1.21
No association between androgen or vitamin D receptor gene polymorphisms and risk of breast cancer. Carcinogenesis (1999) 1.21
Familial cylindromatosis (turban tumour syndrome) gene localised to chromosome 16q12-q13: evidence for its role as a tumour suppressor gene. Nat Genet (1995) 1.21
Analysis and meta-analysis of two serotonin transporter gene polymorphisms in bipolar and unipolar affective disorders. Am J Med Genet (1998) 1.20
Evidence of linkage of the inflammatory bowel disease susceptibility locus on chromosome 16 (IBD1) to ulcerative colitis. J Med Genet (1998) 1.17
Common variants in mismatch repair genes and risk of colorectal cancer. Gut (2008) 1.17
Apparent human BRCA1 knockout caused by mispriming during polymerase chain reaction: implications for genetic testing. Genes Chromosomes Cancer (2001) 1.16
Changing distribution of adenocarcinoma of the stomach. Br J Surg (1987) 1.14
Linked markers flanking the gene for multiple endocrine neoplasia type 2A. Genomics (1989) 1.13
Polymorphisms in the human aromatase cytochrome P450 gene (CYP19) and breast cancer risk. Carcinogenesis (2000) 1.12
Association of PHB 1630 C>T and MTHFR 677 C>T polymorphisms with breast and ovarian cancer risk in BRCA1/2 mutation carriers: results from a multicenter study. Br J Cancer (2012) 1.12
Prostate cancer in BRCA2 germline mutation carriers is associated with poorer prognosis. Br J Cancer (2010) 1.11
Constitutional mutation in exon 8 of the p53 gene in a patient with multiple primary tumours: molecular and immunohistochemical findings. Oncogene (1993) 1.10
No germline mutations in the dimerization domain of MXI1 in prostate cancer clusters. The CRC/BPG UK Familial Prostate Cancer Study Collaborators. Cancer Research Campaign/British Prostate Group. Br J Cancer (1997) 1.10
No association between a polymorphism in the steroid metabolism gene CYP17 and risk of breast cancer. Br J Cancer (1998) 1.09
Tagging single-nucleotide polymorphisms in candidate oncogenes and susceptibility to ovarian cancer. Br J Cancer (2009) 1.08
HapMap-based study of the 17q21 ERBB2 amplicon in susceptibility to breast cancer. Br J Cancer (2006) 1.07
Prognostic factors in non-infiltrating carcinoma of the bladder: a preliminary report. Br J Urol (1982) 1.07
Allelotype of uterine leiomyomas. Cancer Genet Cytogenet (1999) 1.06
The genetic epidemiology of early-onset epithelial ovarian cancer: a population-based study. Am J Hum Genet (1999) 1.06
Cancer mortality in the first degree relatives of young breast cancer patients. Br J Cancer (1992) 1.04
Prophylactic oophorectomy in inherited breast/ovarian cancer families. J Natl Cancer Inst Monogr (1995) 1.04
Absence of evidence for a familial breast cancer susceptibility gene at chromosome 8p12-p22. Oncogene (2000) 1.03
Mortality from respiratory cancer and other causes in United Kingdom chromate production workers. Br J Ind Med (1991) 1.02
Polygenic inherited predisposition to breast cancer. Cold Spring Harb Symp Quant Biol (2005) 1.02
Localisation of the breast-ovarian cancer susceptibility gene (BRCA1) on 17q12-21 to an interval of < or = 1 cM. Genes Chromosomes Cancer (1994) 1.02
Human familial and sporadic breast cancer: analysis of the coding regions of the 17 beta-hydroxysteroid dehydrogenase 2 gene (EDH17B2) using a single-strand conformation polymorphism assay. Hum Genet (1994) 1.01
Analysis of the apo E/apo C-I, angiotensin converting enzyme and methylenetetrahydrofolate reductase genes as candidates affecting human longevity. Atherosclerosis (1997) 1.00
ATM polymorphisms as risk factors for prostate cancer development. Br J Cancer (2004) 1.00
Familial prostate cancer: the evidence and the Cancer Research Campaign/British Prostate Group (CRC/BPG) UK Familial Prostate Cancer Study. Br J Urol (1997) 0.99
FGF receptor genes and breast cancer susceptibility: results from the Breast Cancer Association Consortium. Br J Cancer (2014) 0.96
Common polymorphisms in checkpoint kinase 2 are not associated with breast cancer risk. Cancer Epidemiol Biomarkers Prev (2003) 0.95
Androgen receptor polymorphisms: association with prostate cancer risk, relapse and overall survival. Int J Cancer (1999) 0.94
The management of advanced testicular teratoma. Br J Urol (1988) 0.93
Morphological and immunohistological changes in the skin in allogeneic bone marrow recipients. J Clin Pathol (1984) 0.93
Familial predisposition to breast cancer in a British population: implications for prevention. Eur J Cancer (2000) 0.93
Immunological and histochemical analysis of regional variations of epidermal Langerhans cells in normal human skin. Histochem J (1984) 0.92
No evidence for germline mutations in exons 5-9 of the p53 gene in 25 breast cancer families. Oncogene (1992) 0.91
Decreased breast cancer risk in systemic lupus erythematosus: the search for a genetic basis continues. Lupus (2012) 0.91
The TP53 Arg72Pro and MDM2 309G>T polymorphisms are not associated with breast cancer risk in BRCA1 and BRCA2 mutation carriers. Br J Cancer (2009) 0.90
Testicular microlithiasis as a familial risk factor for testicular germ cell tumour. Br J Cancer (2007) 0.90
The UK national study of magnetic resonance imaging as a method of screening for breast cancer (MARIBS). J Exp Clin Cancer Res (2002) 0.90
The genetics of familial breast cancer and their practical implications. Eur J Cancer (1994) 0.89
HPC2/ELAC2 polymorphisms and prostate cancer risk: analysis by age of onset of disease. Br J Cancer (2002) 0.89
Linkage analysis of chromosome 17 markers in British and South African families with neurofibromatosis type I. Am J Hum Genet (1989) 0.89
Association between the GCG polymorphism of the selenium dependent GPX1 gene and the risk of young onset prostate cancer. Prostate Cancer Prostatic Dis (2002) 0.89
The CEPH consortium primary linkage map of human chromosome 10. Genomics (1990) 0.88
A population study of mutations and LOH at breast cancer gene loci in tumours from sister pairs: two recurrent mutations seem to account for all BRCA1/BRCA2 linked breast cancer in Iceland. J Med Genet (1998) 0.88
Measurement of 1,25-dihydroxyvitamin D3 receptors in breast cancer and their relationship to biochemical and clinical indices. Cancer Res (1984) 0.88
Lymphoid tumours and breast cancer in ataxia telangiectasia; substantial protective effect of residual ATM kinase activity against childhood tumours. Br J Cancer (2011) 0.87
A recurrent truncating germline mutation in the BRIP1/FANCJ gene and susceptibility to prostate cancer. Br J Cancer (2009) 0.87
Linkage analysis of British and Indian families with Von Recklinghausen neurofibromatosis. J Med Genet (1987) 0.87